MiR-200c and HuR in ovarian cancer by Silvia Prislei et al.
Prislei et al. BMC Cancer 2013, 13:72
http://www.biomedcentral.com/1471-2407/13/72RESEARCH ARTICLE Open AccessMiR-200c and HuR in ovarian cancer
Silvia Prislei1, Enrica Martinelli1, Marisa Mariani1,2, Giuseppina Raspaglio1, Steven Sieber2, Gabriella Ferrandina3,
Shohreh Shahabi2, Giovanni Scambia1,3 and Cristiano Ferlini2,3*Abstract
Background: MicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is
the case with members of the miR-200 family, which are the primary regulators of the epithelial to mesenchymal
transition and have been reported to act as both oncogenes and tumor suppressors. This study assessed the role of
miR-200c as regulator of class III β-tubulin (TUBB3), a factor associated with drug-resistance and poor prognosis in
ovarian cancer.
Methods: Expression of miR-200c was assessed in a panel of ovarian cancer cell lines with inherent or acquired
drug-resistance. Stable overexpression of miR-200c was obtained in A2780 and Hey cell lines. Crosslinking-coupled
affinity purification method and ribonucleic-immunoprecipitation assay were used to characterise the complexes
between miR-200c, HuR and 30UTR region of TUBB3 mRNA. Nanofluidic technology and immunohistochemistry
were used to analyze the expression of HuR, TUBB3 and miR-200c in 220 ovarian cancer patients.
Results: In a panel of ovarian adenocarcinoma cell lines, we observed a direct correlation between miR-200c
expression and chemoresistance. In A2780 cells miR-200c targeted TUBB3 30UTR, while a positive correlation was
observed between miR-200c and TUBB3 expression in most of the other cell lines. Through the analysis of
30UTR-associated complexes, we found that the miR-200c can increase the association of the RNA binding protein
HuR with TUBB3 mRNA, whereas HuR binding enhanced TUBB3 mRNA translation. Most importantly, in our analysis
on 220 ovarian cancer patients we observed that overexpression of miR-200c correlated with poor or good
outcome depending on the cellular localization of HuR.
Conclusion: This study suggests a model for the combined regulatory activity of miR-200c and HuR on TUBB3
expression in ovarian cancer. When HuR is nuclear, high expression of miR-200c inhibits TUBB3 expression and
results in a good prognosis, whereas when HuR occurs in cytoplasm, the same miRNA enhances TUBB3 expression
and produces a poor outcome. These findings reveal the usefulness of multidimensional analysis in the
investigation of the prognostic role of miRNA expression.
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About 80% of patients with ovarian cancer respond to
first-line platinum/taxane chemotherapy, but the ma-
jority who experience a relapse will be refractory to fur-
ther treatment [1]. Understanding the molecular events
underlying relapse is essential for identifying patients
at high risk of poor outcome. Several studies reported* Correspondence: Cristiano.ferlini@danhosp.org
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reproduction in any medium, provided the orthat miRNAs can act either as oncogenes or tumor
suppressors [2]. In this context, expression of the miR-
200 family in particular (miR-200a, miR-200b, miR-
200c, miR-141, and miR-429) was linked with ovarian
cancer in multiple reports with contradictory findings.
In some studies, high expression levels of the miR-200
family were associated with early relapse and decreased
overall survival [3-5], while in others the opposite ef-
fect of high miR-200 expression was reported [6-9].
The precise reasons underlying such contradictory
findings remain unknown. The miR-200 family is
known as the main suppressor of the epithelial-to-
mesenchymal transition (EMT), a reversible embryonictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metastasis. While most carcinomas have a differen-
tiated phenotype, ovarian cancer cells that have under-
gone EMT are more invasive and more aggressive
[10,11]. For miR-200s to function as inhibitors of EMT
seems difficult to reconcile with observations that the
miR-200 family of miRNAs is overexpressed in aggres-
sive ovarian cancers [3-5], so the designation of this
family of miRNAs as drivers of biological aggressive-
ness and drug-resistance is a puzzle.
One of the validated targets of the miR-200 family is
TUBB3 (class III β-tubulin) [12], whose overexpression
has been reported in several malignancies, including
ovarian cancer [13]. Posttranscriptional inhibition of
TUBB3 gene expression has been reported for miR-200c
in Hey ovarian cancer cells and in HeC50 endometrial
cancer cells [12,14]. Forced expression of miR-200c in
HeC50 cells and in a xenograft model reversed resist-
ance to chemotherapy [12,14,15] suggesting that miR-
200c is a factor protective against tumor aggressiveness
and chemoresistance. We have shown previously that
TUBB3 gene is conditionally expressed as an adaptive
mechanism of resistance to low oxygen and glucose
levels [16,17], conditions correlated with aggressiveness
in cancer [18]. Interestingly, in hypoglycemic conditions,
TUBB3 is induced by posttranscriptional regulation and
enhanced by association with the RNA-binding protein
(RBP) HuR to the 30UTR region of the mRNA, but the
role of miR-200c in this context is unknown.
The molecular mechanisms whereby HuR modulates
translation are not fully clarified, although it is clear that
HuR regulates numerous genes encoding proteins impli-
cated in carcinogenesis [20]. Nevertheless, an increasing
number of studies have revealed that HuR can modulate
gene expression through its interplay with miRNAs.
Binding of HuR may suppress the inhibitory effect of
miRNAs, although HuR can also synergize miRNAs to
repress gene expression [20-21].
This study aimed to clarify the role of the miR-200c
as driver of biological aggressiveness in ovarian can-
cer. We noticed in vitro a direct correlation between
expression of miR-200 family members and chemore-
sistance in most of the ovarian adenocarcinoma cell
lines analyzed, and in particular we noted a clear cor-
relation between miR-200c and TUBB3 expression.
Using a multidimensional approach, we analyzed TUBB3
(gene and protein), HuR and miR-200c. The results sug-
gested that the same miRNA, miR-200c, can act either
as a suppressor or enhancer of the aggressive pheno-
type, depending upon the localization of HuR. This
result offered a possible explanation for the discrepan-
cies among the clinical reports describing miR-200c as
a suppressor or enhancer of aggressiveness in solid
malignancies.Methods
Cell cultures and reagents
A2780, OVCAR-3, A2780-CIS, and A2780-ADR cells
were purchased from the European Collection of Cell
Cultures. TC1 is a clone derived from A2780 cells
chronically exposed to paclitaxel [22]. OVCAR-EPO
cells correspond to OVCAR-EPO10 cell line obtained
from OVCAR-3 cells as patupilone-resistant, while Hey-
EPO are Hey-derived patupilone resistant cells. Culture
media were selected according to the suggestions of
European Collection of Cell Cultures. Growth experi-
ments and transient transfection with siHuR and siC
oligonucleotide duplex were performed and analyzed as
previously described [16].
A 301-bp DNA fragment including the sequence of
the pre-miR-200c (NT_009759) was amplified with the
primers forward 50-ACAAGCTTAGGAAGTGTCCCCA
GGGACTCG-30 and reverse 50-AACTCGAGACGCTC
TCAGCTCAAGACGAGG-30 and cloned in pUSE(+) ex-
pression vector (Upstate Biotechnology), obtaining the
pUSE-200c plasmid. The empty pUSE vector served as
control. After electroporation, cells were selected in the
presence of G418 (1.5 μg/mL) and when colonies
appeared cloned at limiting dilution. Twelve clones were
screened and those with the highest expression chosen
for further analysis.
Real-time quantitative PCR, Western blotting and
Immunohistochemistry
MiRNAs reverse transcription and PCR reactions were
performed on Trizol (Invitrogen, Carlsbad, CA, USA)
isolated total RNAs using TaqMan MicroRNA Assays kit
(Applied Biosystems, Foster City, CA, USA). Quantitative
PCR on mRNAs was performed as previously described
[16]. Western blots were done on total lysates or on nu-
clear/cytoplasmic fractions as previously described [16],
with the following antibodies: anti-human TUBB3 poly-
clonal (1:1000, Covance, Princeton Township, NJ), anti-
HuR (1:500, Santa Cruz, Santa Cruz, CA), anti-β-actin
(1:5000, Sigma, Saint Louis, MO), anti-SNRP70 (1:1000,
Abcam, Cambridge, UK), anti-GAPDH (1:5000, Abcam,
Cambridge, UK). Blots were visualized by enhanced chemi-
luminescence procedures (Amersham, GE-Healthcare,
Buckinghamshire, UK) as described by the manufacturers.
The expression of HuR and TUBB3 was immunohisto-
chemically assessed in a series of 220 ovarian cancers.
Immunostaining for HuR was performed as previously
described [16]. For the analysis of the expression of
TUBB3, antigen retrieval procedure was performed by
microwave oven heating in 10mM citric acid, pH 6.0
(2 times for 4 min.). TUBB3 protein was identified after
overnight incubation at 4°C by using the monoclonal anti-
human antibody (clone TUJ1;1:300; Covance) in 20% nor-
mal goat serum. The En Vision-mouse+ System-HRP
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dine was used as a chromogen (DAB substrate System,
DAKO). Sections were counterstained with haematoxylin.Luciferase assays
The 292-bp 30UTR sequence of the TUBB3 gene
(NM_006086) was cloned in the XbaI site of pGL3-
Promoter Vector (Promega, Madison, WI), downstream
of the firefly luciferase coding region, obtaining the
pGL3-TUBB3-UTR construct. pGL3-TUBB3-UTRm vec-
tor was derived by inverse PCR on pGL3-TUBB3-UTR
plasmid, resulting in a 10-bp deletion (GCAGTATTTA)
which includes the seed sequence for miR-200c. The con-
trol vector pGL3-V was obtained cloning a 445-bp se-
quence from the MCS of pBluescript SK (nt 977–532) in
the XbaI site of pGL3-Promoter Vector. A2780 cells were
transfected with the described reporter vectors together
with the renilla luciferase normalization plasmid (pRL-
TK), using Transfectin (Bio-Rad, Hercules, CA). Cells
were harvested 48 hours later for analysis using Dual Luci-
ferase Reporter assay system (Promega, Madison, WI).Purification of S1-tagged mRNPs and RIP assay
The UTR-S1 vector was obtained inserting in pUSE(+) ex-
pression vector (Upstate Biotechnology, Lake Placid, NY)
the following sequences: 1) the coding sequence of the
firefly luciferase and the TUBB3 30UTR region, amplified
from the described pGL3-UTR construct; 2) the linker se-
quence L1 amplified from pBluescript SK vector (nt 701–
825); 3) the S1 aptamer sequence, obtained by annealing
the primers tag-S1-F 50-AATTCACCGACCAGAATCA
TGCAAGTGCGTAAGATAGTCGCGGGCC-30 and tag-
S1-R 50-GGCCGCCCCGGCCCGCGACTATCTTACGC
ACTTGCATGATTCTGGT-30. The UTRm-S1 vector dif-
fers from UTR-S1 for the mutation already described in
pGL3-UTRm construct. The S1-tagged reporter con-
structs were stably transfected in A2780 cell line as
described above and the expression of the exogenous
mRNA was quantified by Q-PCR with primers LUC-F1
50-CTTACTGGGACGAAGACGAACAC-30 and LUC-R1
50-GGGAAGACCTGCGACACCTG-30. The purification
of the S1-tagged mRNA/RBP was performed on cells
treated with glucose-free medium for 48 hours, then
incubated with 0.2% formaldehyde for the cross-linking
and processed as described-by Vasudevan & Steitz [23].
Western blot were performed with the antibody anti-
Ago2 (1:250, Abcam, Cambridge, UK) and anti-HuR
(1:500, Santa Cruz, Santa Cruz, CA). RIP was performed
as described [16], with the modification of treating the
cells in 0.2% formaldehyde before the harvesting, as
above described for purification of S1-tagged mRNA/
RBPs.Nanofluidic analysis of micro-RNA and gene expression
FFPE samples were obtained from ovarian cancer that
had been preserved between 2000 and 2008 following
the approved Danbury Hospital Internal Review Board
protocol. FFPE samples were cut to 10 μm thickness and
two tissue slices were put into a 1.5 ml tube. One milli-
liter of xylene was added for deparaffinization followed
by mixing twice with a high speed vortex for 3 min at
room temperature. Total RNA was then automatically
extracted with the QIAcube using the Qiagen miRNeasy
FFPE kit (Valencia, CA) following manufacturers’ proto-
cols. The RNA from the cell line A2780 was automatic-
ally extracted with the QIAcube using the Qiagen
miRNeasy kit (Valencia, CA) following manufacturer’s
protocols. RNA quantity and the quality were assessed
by Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Analysis was carried out using the
48.48 dynamic array (Fluidigm Corporation, CA, USA)
and a Biomark platform following the manufacturer’s
protocol.
Statistical analysis
Overall survival (OS) and progression free survival (PFS)
were calculated from the date of diagnosis to the date of
progression/death or date last seen. Medians and life
tables were computed using the product-limit estimate
by the Kaplan-Meier method and the Wilcoxon test was
employed only to assess statistical significance. Multi-
variate analysis assessed the clinical role of TUBB3,
miR-200c, HuR pattern of staining in a model including
additional significant variables in univariate analysis
such as (age, stage and histotype) using the Cox propor-
tional hazards model and nonparametric testing with the
Kruskal Wallis test. T-test served to test differences of ex-
pression among different cells/conditions. A P value<0.05
was considered significant. Statistical analysis was carried
out using JMP9 (SAS).
Results
Expression of the miR-200c in drug-resistant ovarian
adenocarcinoma cell lines
Expression of miR-200c was assessed in a panel of ovar-
ian cancer cell lines with differing sensitivities to pacli-
taxel and cisplatin (Figure 1A). A2780 cells are markedly
more drug-sensitive than OVCAR-3, Hey, SKOV-6, and
OV2774 cell lines, while its derivatives A2780-ADR,
A2780-CIS, and A2780-TC1 show acquired chemoresis-
tance to different extents. OVCAR-EPO and Hey-EPO
cells were obtained from OVCAR-3 and Hey cells, re-
spectively, and show resistance to patupilone treatment
but a heightened sensitivity to paclitaxel and cisplatin,
compared to the parental cell lines [24,25].
Q-PCR analysis of the miR-200c in the aforemen-












































1 2   3    4   5 6   7 8   9  10
1 2 3 4 5 6 7 8 9 10
A2780 A2780-ADR A2780-CIS TC1 OVCAR-3 OVCAR-EPO Hey Hey-EPO SKOV-6 OV2774
Paclitaxel 0.003 ± 0.0005 1.24 ± 0.265 0.003 ± 0.0002 10 ± 3.2 0.022 ± 0.002 0.014 ± 0.003 0.01 ± 0.002 0.005 ± 0.001 0.036 ± 0.007 0.0029 ± 0,0004
Cisplatin 0.485 ± 0.006 2 ± 0.49 7.9 ± 2.3 2.6 ± 0.28 1.8 ± 0.254 0.539 ± 0.106 2.36 ± 0.504 0.96 ± 0.247 3.687 ± 0.122 2.835 ± 0.491
HuR





Figure 1 A: Table reporting the IC50 in μmol/L for paclitaxel and cisplatin in the used panel of ovarian cancer cell lines. The cell lines
are numbered progressively and the same numbers are used to indicate the lane in which each cell line was analyzed. B and C: Analysis of miR-
200c and TUBB3 mRNA expression, respectively, in the cell lines numbered as in panel A. Bars and error bars refer to mean and SD of two
experiments performed in triplicate. In bar charts expression was normalized on the level measured in A2780 cells (=1). D and E: Representative
Western Blot for the expression of TUBB3 and HuR, respectively,in the cell lines numbered as in panel A. The Coomassie is used as loading
control. The asterisk indicated the mitochondrial form of TUBB3. F: Western blot analysis of HuR expression on A2780 and OVCAR-3 nuclear (nu)
and cytoplasmic (cyt) fractions. SNRP70 and GAPDH were utilized as markers of nuclear and cytoplasmic extracts respectively. The protein content
were used as loading control.
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genic cells, regardless of whether resistance to paclitaxel
and cisplatin was inherent or acquired (Figure 1B). The
only exception was the expression in the Hey cell line,
which was approximately the same as in A2780 cells,
while miR-200c expression was fourfold higher in Hey-
EPO cells.
Correlation between miR-200c and TUBB3 expression in
drug-resistant cell lines
Because TUBB3 is among the factors associated with
drug-resistance in ovarian cancer, we set out to investi-
gate the correlation between TUBB3 expression and ex-
pression of miR-200c in the same panel of cell lines. The
highest TUBB3 mRNA and protein expression is observed
in cell lines with native chemoresistance (OVCAR-3, Hey,SKOV-6, and OV2774 cells), but a marked increase in ex-
pression is also evident in A2780-derived cell lines with
acquired drug-resistance (Figure 1C-D). OVCAR-EPO and
Hey-EPO cells showed decreased TUBB3 expression com-
pared with parental cells, as we reported previously, since
epothilones seemed capable of selectively killing off those
cells with high levels of TUBB3. Comparisons between
TUBB3 and miR-200c expression revealed a direct correl-
ation (R=0.49, p=0.03) in the majority of the cells analyzed.
The only exception was in Hey and Hey-EPO cells, where
an inverse correlation was observed between TUBB3 and
miR-200c expression.
Since HuR is involved in the control of TUBB3 trans-
lation [16], HuR expression was analyzed in the same
panel of cells. The total amount of HuR protein did not
show evident correlation with TUBB3 expression in
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cytoplasmic ratio of HuR in the different cell lines was
different in normoglycemia, with A2780 exhibiting a
prevalent nuclear HuR localization, while in OVCAR-3
the localization was mostly in the cytoplasm (Figure 1F).
Recent studies demonstrated that TUBB3 expression
is indeed modulated by miR-200c in Hey cells and in
Hec50 endometrial cancer cells [12,14]. In order to ver-
ify this effect in A2780 cells, two cell clones overexpres-
sing miR-200c were generated from A2780 cells. As
compared with the cells transformed with the empty


















































Figure 2 A: Expression analysis of miR-200c in A2780 cells transforme
overexpressing the miR-200c (200c-5 and 200c-14). B: Bar chart of TUB
refer to mean and SD of two experiments performed in triplicate. It is clear
gene in a significant way (double asterisks= P<0.001). The same phenomen
the protein level. Actin served as a loading control. D: Schematic represent
assays on A2780 cells transfected with the reporter vectors pGL3-TUBB3-UT
units were calculated normalizing the firefly values for the renilla values. A
miR-200c is overexpressing cells . F-G: Line charts reporting dose–response
paclitaxel (F) and cisplatinum (G). Colonies were counted 14 d after drug trmore than two-hundred fold miR-200c expression
(Figure 2A). The 200c-5 and 200c-14 clones exhibited
also a remarkable significant inhibition of TUBB3 at the
gene and protein level (Figure 2B-C). A luciferase-based
assay was performed to investigate the direct activity of
miR-200c on TUBB3 regulation. TUBB3 30UTR was
cloned downstream of the firefly luciferase gene in a re-
porter vector (pGL3-TUBB3-UTR, Figure 2D) and
mutagenized into the predicted interaction site (pGL3-
TUBB3-UTRm vector). A plasmid carrying a sequence
from the pBluescript vector was prepared as control












d with the empty vector (pUSE) and in two clones
B3 mRNA expression obtained in the same cells. Bars and error bars
ly visible that overexpression of miR-200c inhibits expression of TUBB3
on is evident in the western blot (C) showing the TUBB3 expression at
ation of the constructs utilized for the luciferase assays. E: Luciferase
R, pGL3-TUBB3-UTRm or the control pGL3-V. The relative luciferase
clear inhibition is noticeable when pGL3-TUBB3-UTR is transfected in
curves obtained in A2780-pUSE, 200c-5 and 200c-14 cells treated with
eatment.
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Figure 3 A: Representative western blot analysis of TUBB3
expression on A2780 miR-200c overexpressing clones (200c-5
and 200c-14) relative to A2780 transfected with the empty
vector (A2780-pUSE) upon treatment in hypoglycemia for 72
hours (left panels). The same treatment was also performed on
OVCAR-3 cells (right panels). The total protein content was used as
loading control. The asterisk indicated the mitochondrial form of
TUBB3. B: Densitometric analysis of the bands of panel A. Values are
expressed as percentage relative to the untreated controls. Bar and
error bars represent the mean and SD of two independent
experiments. Only in PUSE there was an increase in hypoglycemia of
TUBB3 expression which was significant. C: qPCR analysis of miR-
200c expression on A2780 and OVCAR-3 cells as indicated, upon
treatment in hypoglycemia, conditions for hours. Values are
expressed as percentage relative to the untreated controls. In the
two cellular models the opposite significant (asterisk=P-value <0.05)
trend for miR-200c expression was noticed.
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clone with the highest expression of miR-200c. The
pRL-TK vector served to normalize firefly luciferase ex-
pression. Luciferase expression driven by pGL3-UTRm
was 1.6-fold higher as compared with pGL3-UTR in
A2780 cells, demonstrating that the predicted site of
interaction with miR-200c was indeed recognized by anegative regulator (Figure 2E). Overexpression of miR-
200c caused a significant inhibition of the reporter activity,
while this phenomenon disappeared when the mutated
pGL3-TUBB3-UTRm vector was used (Figure 2E). These
findings demonstrated that miR-200c is a repressor of
TUBB3 expression in A2780 cells through an interaction in
the 30UTR of the gene, as described previously by Cochrane
and colleagues in Hey cells [12]. To investigate the possible
role of miR-200c in drug resistance, clonogenic and growth
inhibition assays were performed on clones that over-
expressed miR-200c. Paclitaxel and cisplatin exhibited an
increased activity in both clones as compared to control
cells (Figure 2F-G). As an additional parameter for gauging
cell proliferation, the total colony area was measured and a
decrease was noted in the miR-200c overexpressing cells
treated with paclitaxel and cisplatin (data not shown).
These results are in line with previous evidences that
TUBB3 downregulation is responsible for increased sensi-
tivity to cisplatin and paclitaxel [24,26].
Hypoglycemia and miR-200c control of TUBB3 expression
TUBB3 expression is induced by hypoxia and hypoglycemia,
conferring increased drug-resistance on A2780 cells [16,17].
To analyze the possible involvement of miR-200c in
stress-induced TUBB3 expression, A2780 miR-200c
overexpressing cells were cultured in hypoglycemic con-
ditions for 72 hours, after which time the TUBB3 pro-
tein level was assessed (Figure 3A-B). While TUBB3
protein induction was evident in control pUSE cells, a
just detectable increase was noticed in miR-200c overex-
pressing cells, suggesting that miR-200c was capable to
inhibit the overexpression of TUBB3 gene under stres-
sing conditions.
TUBB3 protein expression was also analyzed in the
OVCAR-3 cell line, featured with high levels of TUBB3
and miR-200c (see Figure 1B-D). In this model,
hypoglycemia induced a faint not significant increase
(Figure 3A-B). This finding suggested that TUBB3 ex-
pression cannot be increased over a certain level in this
cell line, at least in the conditions analyzed.
Endogenous miR-200c expression was assayed in
A2780 and OVCAR-3 cells cultured in hypoglycemic
conditions (Figure 3C). In A2780 cells miR-200c expres-
sion decreased, while in the same conditions it increased
in OVCAR-3. Overall, these results suggested that
A2780 and OVCAR-3 cell lines represent two different
models, and prompted us to investigate the mechanism
of miR-200c in regulation of TUBB3 expression, analy-
zing the involvement of additional factors.
Analysis of the interaction of miRNA-200c and HuR in
modulation of TUBB3 expression
We reported previously that HuR mediates increased trans-






















































Figure 4 A: The scheme above represented the TUBB3 30UTR region, with the miR-200c binding site and the HuR binding region,
according to [12,27]. The schematic representations of the S1-tagged constructs were shown below, as the method utilized for the purification
of the mRNP complexes. B: qPCR analysis of the luciferase expression in A2780 cells stably transfected with UTR-S1 or UTRm-S1 vectors and
cultured in hypoglycemia for 48 hours (− glucose), in comparison with the expression in normoglycemia (+ glucose). C: qPCR analysis of the
exogenous mRNAs recovery (LUC), upon mRNA/RBP complexes purification as indicated in panel A. A2780 cells expressing either UTR-S1 or
UTRm-S1 vectors were cultured in hypoglycemia (−) or in normoglycemia (+) for 48 hours. The values are expressed as percentage relative to
input mRNAs. As control also the recovery of RNA polymerase II mRNA was analyzed (RNApol). D: Representative Western blot analysis of Ago2
and HuR proteins in streptavidin-bound complexes (S1-bound) and in extracts not bound to streptavidin (S1-unbound) purified from cell lines as
in panel C.
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miRNA-mediated suppression by HuR [20,21,28], we
explored the possible interactions between HuR and miR-
200c in modulating TUBB3 mRNA. The study of mRNA/
protein complexes in vivo is often hampered by the rapidity
of the interactions and by nonspecific binding of abundant
RBPs. To overcome these limitations we set up an in vivo
cross-linking–coupled RNA/RBP purification assay. We
obtained a vector in which the TUBB3 30UTR region was
followed by an S1 sequence, an RNA aptamer which binds
the streptavidin (UTR-S1, Figure 4A), along with the
UTRm-S1 vector, in which the tagged 30UTR sequence fea-
tured a mutation at the miR-200c interaction site
(Figure 4A). After the stable transfection in A2780 cells and
the treatment of the cells in hypoglycemic conditions, we
checked that the expression of exogenous mRNAs was
similar in A2780-UTR-S1 and A2780-UTRm-S1 cell lines
in normoglycemia, as well as upon hypoglycemic treatment
(Figure 4B). The analysis of specific RNAs and RNA-
binding proteins associated in the S1-complexes was per-
formed. We verified that the recovery of the exogenousmRNAs was similar in A2780-UTR-S1 and A2780-UTRm-
S1 cell lines in normoglycemia, as well as upon
hypoglycemic treatment (Figure 4C). The RNA polymerase
II mRNA, analyzed as a negative control, was indeed
detected at a much lower rate in the complexes
(Figure 4C).
Western blot analysis revealed that HuR binding on
UTR-S1 mRNA increased with hypoglycemic conditions,
whereas binding on UTRm-S1 mRNA decreased under
these conditions (Figure 4D). Ago2 binding was detectable
in hypoglycemic conditions on UTR-S1 mRNA, but not on
UTRm-S1 mRNA (Figure 4D). The S1-unbound samples
were utilized as controls. MiR-200c was needed for the
interaction of Ago2 with the TUBB3 30UTR, since the dele-
tion of its seed sequence prevented the association of any
RISC containing Ago2, suggesting that miR-200c is the
main miRNA interacting with TUBB3 30UTR. What is
more, these data support the notion that miR-200c inter-
acted with the TUBB3 30UTR in hypoglycemia and that
such an interaction was important for HuR binding and
increased expression of TUBB3 under stressing conditions.
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200c seemed to be capable of acting as a positive regulator
of TUBB3 expression and as a factor determining biological
aggressiveness.
To further demonstrate the presence of a complex involv-
ing HuR, TUBB3 mRNA and miR-200c, ribonucleoprotein-
immunoprecipitation (RIP) with anti-HuR antibody was
performed on A2780 cells treated in hypoglycemic condi-
tions. As normalized for the values detectable in the un-
bound fraction, there was a specific enrichment of miR-
200c in the HuR-complexes in A2780 cells (Figure 5A). The
RIP assay was also performed in A2780 control cells
(A2780-pUSE) in the A2780-200c-14 clone, in Hey and
OVCAR-3 cells (Figure 5B-D). All these cells are featured
by diverse levels of miR-200c, as previously shown
(Figure 1B and 2A). The recovery of TUBB3 mRNA
associated with HuR was dramatically enhanced when
the levels of miR-200c were higher, as it occurs in
200c-14 clone and in OVCAR-3 cells (Figure 5B). As
control, also the level of HPRT in the HuR-complexes
was measured. The miR-200c analysis of RIP com-













Figure 5 A: Bar chart of ribonucleoprotein-immunoprecipitation (RIP)
of hypoglycemia with anti-HuR antibody and with an irrelevant anti I
complexes was quantified by normalization with the corresponding not im
=1. B-C: Bar charts of RIP performed in A2780, A2780-pUSE, A2780-200c-14
an irrelevant anti IgG antibody. Statistical comparison was performed only
compared to A2780 parental cells while § marks the difference as compare
analysis of TUBB3 mRNA, HPRT mRNA, miR-200c and miR-200a present in t
and the corresponding not immunoprecipitated extracts. Values were normof miR-200c in OVCAR-3 and 200c-14 cells, while
such phenomenon was not observed for miR-200a,
utilized as control (Figure 5C). Overall, the obtained
results strongly suggested the interplay of miR-200c
complex and HuR in regulation of TUBB3 expression.
The same strategy adopting the luciferase reporter
assay was also attempted in OVCAR-3 and OV2774
cells in the presence of HuR silencing. The expression
of the artificial reporter was barely detectable in mul-
tiple experiments, likely for the competition of the
high expression of the natural TUBB3 gene (data not
shown).
The relevance of HuR in the control of TUBB3 transla-
tion, already reported in the A2780 cells [16], was studied
also in the different models of OVCAR-3 and OV2774 cells
(Figure 6). The HuR silencing by transient transfection in
A2780 cells reverted the induction of TUBB3 expression in
hypoglycemia, while in the OVCAR-3 and OV2774 cells
the decrease of TUBB3 expression is detectable also in
basal conditions. These results confirmed the significance




performed on A2780 cells in normoglycemia and after 48 hours
gG antibody. The qPCR analysis of miR-200c present in the RIP
munoprecipitated extracts. Data were shown as relative RIP, as IgG (+)
, Hey and OVCAR-3 cells as indicated with anti-HuR antibody and with
among isogenic cells. Asterisk mark the significant differences as
d to pUSE cells. For both significance was set at a P<0.05. The qPCR
he RIP complexes was quantified by normalization with anti-IgG RIP
alized for the levels obtained in A2780 cells (=1).
Table 1 Clinical features of the analyzed setting of
ovarian cancer patients












Clear Cell 13 (5.9)
Undifferentiated 10 (4.5)
Adenocarcinoma (not specified) 3 (1.4)
Ca 125




Median follow up (Alive) 71 months
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ovarian cancer patients
A retrospective analysis was carried out in 220 ovarian
cancer patients to assess the clinical relevance of our
findings. Clinical features of this study subset are sum-
marized in Table 1. Analysis of miR-200c and TUBB3
gene expression was performed using a nanofluidic gen-
etic analyzer and a 48.48 chip array. As control miRNAs,
RNU44 and MAMMU6 were used, while for TUBB3 as-
sessment, housekeeping was performed by GAPDH. All
results were normalized with expression levels measured
in A2780 cells (=1). As reported previously [13], the me-
dian served as the cut-off value to identify groups of
patients negative and positive for miR-200c and TUBB3
mRNA expression. HuR and TUBB3 staining was per-
formed using immunohistochemistry (Figure 7A). A cer-
tified pathologist scored the samples as bearing only
nuclear (HuR N) or both a nuclear and cytoplasmic pat-
tern of staining (HuR C) without any prior knowledge of
clinical or biological results. Similarly, the pathologist
scored TUBB3 protein expression and patients were
categorized as demonstrating high or low TUBB3 ex-
pression according to the percentage of positive cells, if
above or below the median 20%, respectively. Of the 220
patients analyzed, 186 patients expressed detectable
amounts of all 3 factors (HuR, TUBB3, and miR-200c).





















































Figure 6 Western blot analysis of TUBB3 and HuR expression on A2780, OVCAR-3 and OV2774 cells untrasfected (“untr” lanes) or
transfected with siC and siHuR, as indicated. Cells were cultured in normoglycemia (+) or in hypoglycemia (−) for 48 hours (for methods
details, see [16]). The asterisk indicated the mitochondrial form of TUBB3. Actin served as loading control. Densitometric analysis of the TUBB3
bands corresponding to the TUBB3 cytoplasmatic form is shown on the bottom side of the panels and values are expressed as percentage











































Figure 7 A: Representative immunohistochemistry for HuR (upper panels) and TUBB3 (lower panels) on ovarian cancer samples. The
panels on the left represent an ovarian cancer with a nuclear staining pattern for HuR (Hur N, see text) and a faint staining of TUBB3; the panels
on the right represent a sample with a nuclear and cytoplasmic staining pattern for HuR (Hur C) and a marked staining of TUBB3 (magnification
400X). In insets, lower magnification is shown. B: Kaplan Meier analysis of overall survival (top) and progression free survival (bottom) for ovarian
cancer patients according to TUBB3 protein expression. P values are added when the differences between the two curves are significant by
Wilcoxon test.
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http://www.biomedcentral.com/1471-2407/13/72protein expression alone was an outstanding biomarker
(Figure 7B), and we noted a significant positive correl-
ation between gene and protein expression for TUBB3,
with an R value of 0.67 (p<0.0001). However, as we
reported previously [16], its predictive role was mainly
confined to the HuR C pattern (Table 2). Patients with
high levels of TUBB3 (i.e., from gene or protein) exhib-
ited early relapse and shorter survival when the pattern
of staining was HuR C. This association underscores the
importance of the HuR-mediated TUBB3 enhancementof translation in the cytoplasm. We analyzed the data
taking into consideration the expression levels of miR-
200c. In keeping with the hypothesis derived from
in vitro experiments, patients exhibiting high expression
levels of TUBB3, miR-200c, and HuR C emerged with
the worst outcome, while patients in whom low expres-
sion of TUBB3, high miR-200c and HuR N were found
exhibited the best prognosis (Figure 8A-B). In the first
category, the 5-year survival rate was only 6.7 percent,
while in the second it was 52 percent (Table 3). In order
Table 2 Survival rates of different groups of patients
Alive Dead Survival Rate
HuR C- TUBB3+ miR-200c- 10 21 32.2%
HuR C- TUBB3+ miR-200c+ 1 14 6.7%
HuR C- TUBB3- miR-200c- 13 15 46.4%
HuR C- TUBB3- miR-200c+ 4 14 22.2%
HuR N- TUBB3+ miR-200c- 9 14 39.1%
HuR N- TUBB3+ miR-200c + 3 10 23.0%
HuR N- TUBB3- miR-200c- 15 22 40.5%
HuR N- TUBB3- miR-200c + 11 10 52.0%
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http://www.biomedcentral.com/1471-2407/13/72to link clinical features with TUBB3 expression, we ana-
lyzed TUBB3 protein levels according to the expression
of miR-200c and the HuR staining pattern (Figure 8 C-
D). In patients exhibiting the HuR N pattern and high
miR-200c, we detected the lowest TUBB3 expression,
while in patients with high miR-200c and the HuR C
pattern, we found the highest levels of TUBB3 expres-
sion; the difference was statistically significant (p value <
0.0001). These findings from our translational study
clearly demonstrate that the predictive activity of miR-






Figure 8 (A-B) Kaplan Meier Analysis of overall survival (A) and progr
HuR pattern/TUBB3 protein expression/miR-200c expression. P values
significant by Wilcoxon test. (C-D) Box-plot representing the TUBB3 protein
high levels of miR-200c (C) and low levels of miR-200c (D). Lines represent
and the DS interval. Data show that patients with high expression of miR-2
to HuR pattern of staining.Discussion
Ovarian cancer is a very heterogeneous disease. Tumors
that underwent the epithelial to mesenchymal transition
(EMT) are in general less differentiated and more inva-
sive, aggressive, and chemoresistant. Nevertheless, a
paradox appears at molecular level in ovarian cancer
patients: although indicated as suppressors of EMT,
enhanced expression of the miR-200 family was asso-
ciated with early relapse and decreased overall survival
[3-5]. In keeping with these findings, our results indi-
cated a direct correlation between miR-200c expression
and chemoresistance to paclitaxel and cisplatin in a
panel of ovarian adenocarcinoma cell lines with inherent
or acquired drug-resistance. In apparent contrast with
these findings, in previous reports miR-200c was capable
of sensitizing Hey and HeC50 cells to the effects of
chemotherapy through downregulation of the TUBB3
gene [12,14]. In the A2780 model we employed, lucifer-
ase reporter assays and exogenous overexpression con-
firmed this dynamic and established that miR-200c acts
as a negative regulator of 30UTR TUBB3 mRNA. Along
with TUBB3 downregulation, in this study we reported
that the level of resistance to paclitaxel and cisplatin was
associated with the expression level of miR-200c in





































ession free survival (B) for ovarian cancer patients according to
are added when the differences between the two curves are
expression according to HuR pattern of staining in patients expressing
the range of the expression while diamond plots represent the mean
00c have significant differences in TUBB3 protein expression according
Table 3 Survival rates at 5 years and Odds Ratio (OR) for different groups of patients obtained through COX
regression multivariate model
Alive Dead Survival Rate OR CI (0.05-0.95)
HuR C- TUBB3+ miR-200c + 1 14 6.70% 2.02 1.11–3.62
HuR C- TUBB3- miR-200c + 4 14 22.20% 0.92 0.48–1.73
HuR N- TUBB3+ miR-200c + 3 10 23.00% 1.87 0.84–3.18
HuR C- TUBB3+ miR-200c - 10 21 32.20% 1.46 0.75–2.74
HuR N- TUBB3+ miR-200c - 9 14 39.10% 1.24 0.52–2.63
HuR N- TUBB3- miR-200c - 15 22 40.50% 1
HuR C- TUBB3- miR-200c - 13 15 46.40% 1.35 0.59–2.53
HuR N- TUBB3- miR-200c + 11 10 52.00% 1 0.541–1.82
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http://www.biomedcentral.com/1471-2407/13/72200c is capable of suppressing TUBB3 expression, as
reported previously by Cochrane and colleagues [12,14].
However, this phenomenon is not general and in some
cell lines such regulation is not detectable; in fact,
exactly the opposite dynamic was observed. In cells with
high TUBB3 expression, either with inherent or acquired
resistance to paclitaxel/cisplatin, miR-200c expression
was enhanced. How is it possible to reconcile these
seemingly contradictory findings? Under specific cellular
conditions, miRNA-mediated repression was prevented
or reversed, and the inhibitory effect of miRNAs was
modulated by RBPs acting on the same mRNA. Among
the RBPs that antagonize or facilitate miRNA-mediated
repression, a prominent factor is HuR, which affects sta-
bility and the translation of numerous genes implicated
in cancer aggressiveness [19], including TUBB3 [16].I I I I











Figure 9 Model proposing different mechanisms of miR-200c regulat
confined in the nucleus (HuR N), miR-200c behaves as a repressor, mediatin
protein expression is linked to a good response to chemotherapy and a fa
(HuR C), the interaction with miR-200c-RISC on TUBB3 mRNA induces spec
stability. This will yield up-regulation of TUBB3 protein, drug-resistance andThe ability of HuR to modulate TUBB3 mRNA expres-
sion is closely linked to its translocation into the cyto-
plasm, since it is dependent on the direct enhancement
of translation of TUBB3 under stressing conditions.
Using an S1-tagged RNP purification strategy, we discov-
ered that, in A2780 cells, the miR-200c complex binds
to the 30UTR region in hypoglycemic conditions, and
that such interaction increases HuR binding. At variance
with the inverse relationship between miRNA expression
and downregulation of this target, miRNA-mediated
binding to HuR is capable of stimulating protein expres-
sion. This phenomenon appeared in vitro in some cell
lines, but most importantly it also appeared in a clinical
setting in which material from 220 ovarian cancer
patients was analyzed. When the HuR pattern of staining
was only nuclear, the prevalent mechanism by whichHuR C
me
I I I I














ory activity on TUBB3 mRNA in ovarian cancer. When HuR is
g TUBB3 mRNA decay (right panel). The resulting low levels of TUBB3
vorable outcome. On the contrary, if HuR is expressed in the cytoplasm
ific pickup of TUBB3 gene into ribosomes and enhancement of mRNA
early relapse with a poor outcome.
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TUBB3 gene/protein expression, and as a consequence
the tumor exhibited a good outcome. In contrast, when
HuR localization was also cytoplasmic, the role of miR-
200c appeared to be just the opposite, i.e., the stimula-
tion of TUBB3 protein expression. In the latter case, we
theorized that miR-200c promoted interaction with HuR
in the cytoplasm and increased the translation of
TUBB3, as summarized in the model of Figure 9. To our
knowledge this is the first study that showed the same
miRNA was capable of promoting opposite effects on
the expression of one of its targets, depending on its
interaction with an RBP such as HuR. This information
could be valuable from a clinical perspective, because
ovarian cancer is generally an aggressive disease diag-
nosed at an advanced stage, in which average 5-and 10-
year survival in the US is 33% and 22%, respectively
(SEER database, http://seer.cancer.gov). In this report,
we demonstrated that the same trends observed in cell
lines are detectable in patients. A good outcome, better
than average, can be predicted for those patients who
exhibit ovarian cancer with nuclear HuR pattern, high
levels of miR-200c, and low levels of TUBB3. On the
other hand, patients with HuR cytoplasmic staining and
high expression of TUBB3 and miR-200c have the worst
outcomes and the highest risk of death. This finding
reveals the importance of multidimensional analysis
when assessing the impact of miRNAs on gene expres-
sion, and it explains the discrepancies reported in the lit-
erature that analyzes the expression of miR-200c alone,
claiming it as a marker of both poor [3-5] and good out-
come [6-9]. We conclude that only the combined assess-
ment of miR-200c, HuR, and TUBB3 is useful for
tailoring specific protocols aimed at differentiating ap-
propriate treatment modalities in ovarian cancer.Conclusions
In summary, the results of our study revealed that HuR
plays a pivotal role in driving TUBB3 expression and the
aggressive phenotype in ovarian cancer, through its
interaction with miR-200c. We are confident that this
discovery will foster the development of protocols spe-
cific to ovarian cancer patients. These findings suggest
the complex HuR/miR-200c/TUBB3 as a new potential
target for the development of therapies aimed at over-
coming aggressive disease in ovarian cancer patients.
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